Skip to main content

Mark Lebwohl, MD

Mark Lebwohl, MD

Professor and Chairman, Department of Dermatology
Icahn School of Medicine at Mount Sinai
New York, New York USA

Related Videos

Many dermatologists—and patients—are asking whether, during the Covid-19 pandemic, biologics such as dupilumab should be stopped in patients with AD? What are your recommendations?

Many dermatologists—and patients—are asking whether, during the Covid-19 pandemic, biologics such as dupilumab should be stopped in patients with AD? What are your recommendations?

What is the approach to sequencing therapy for moderate-to-severe AD, what are the risks for established agents, and how have type 2 cytokine-signaling inhibitors such as dupilumab changed our approach to sequencing in the younger population?

What is the approach to sequencing therapy for moderate-to-severe AD, what are the risks for established agents, and how have type 2 cytokine-signaling inhibitors such as dupilumab changed our approach to sequencing in the younger population?

How do you transition pediatric or adult patients who may already be on other systemic agents such as cyclosporine or methotrexate to dupilumab? Can you provide practical guidance that is applicable to the front lines of AD care?

How do you transition pediatric or adult patients who may already be on other systemic agents such as cyclosporine or methotrexate to dupilumab? Can you provide practical guidance that is applicable to the front lines of AD care?

Are there specific clinical phenotypes that are uniquely responsive to inhibition of type 2 cytokine-signaling proteins, or do patients across the moderate-to-severe spectrum of AD seem to respond with predictable success?

Are there specific clinical phenotypes that are uniquely responsive to inhibition of type 2 cytokine-signaling proteins, or do patients across the moderate-to-severe spectrum of AD seem to respond with predictable success?

Can you share a case of a pediatric patient with AD who required intensification of therapy with a systemic, immunotherapeutic agent? What were the specific triggers for deploying a type 2 cytokine-signaling protein inhibitor such a dupilumab?

Can you share a case of a pediatric patient with AD who required intensification of therapy with a systemic, immunotherapeutic agent? What were the specific triggers for deploying a type 2 cytokine-signaling protein inhibitor such a dupilumab?

Can you give us a sense of the disease burden—physiological, symptomatic, and psychological—associated with atopic dermatitis (AD) in children and adolescent patients; and to what degree is it, or can it be, truly debilitating?

Can you give us a sense of the disease burden—physiological, symptomatic, and psychological—associated with atopic dermatitis (AD) in children and adolescent patients; and to what degree is it, or can it be, truly debilitating?

What is the take home lesson about biologic therapy for AD and what does the future hold? What are the continuing unmet needs?

What is the take home lesson about biologic therapy for AD and what does the future hold? What are the continuing unmet needs?

Now that dupilumab has received formal FDA approval for use in the 6-11 age group, can you share what your clinical experience has been using this biologic in the pre-adolescent, pediatric age group?

Now that dupilumab has received formal FDA approval for use in the 6-11 age group, can you share what your clinical experience has been using this biologic in the pre-adolescent, pediatric age group?

After what length of treatment with dupilumab do you expect to see a clinical response in pediatric patients, how long do you expect the response to last, and what is your recommendation as far as duration of therapy with dupilumab?

After what length of treatment with dupilumab do you expect to see a clinical response in pediatric patients, how long do you expect the response to last, and what is your recommendation as far as duration of therapy with dupilumab?